touchRESPIRATORY coverage of ATS 2025: The annual American Thoracic Society (ATS) International Conference 2025 brought together leading pulmonologists, researchers, and respiratory therapists to explore the latest advances in lung disease diagnosis, treatment, and management. From breakthrough therapies in chronic obstructive pulmonary disease and interstitial lung disease to cutting‑edge innovations in mechanical ventilation and pulmonary rehabilitation, ATS 2025 showcased transformative science and clinical practice.
We’re excited to present a series of expert interviews featuring thought leaders discussing key trial results, practical implementation strategies, and real‑world studies. Whether you’re seeking insights into emerging biologics, strategies to optimize ICU care, or pathways to improve long‑term patient outcomes, our conference coverage provides high‑value perspectives tailored for respiratory healthcare professionals. Stay tuned for in‑depth interviews that translate conference highlights into clinical impact.
Breaking the Vicious Vortex: Targeting Pseudomonas Aeruginosa Infection in Bronchiectasis – Insights from GREAT-2
An interview with Dr Merete Long.
Improved COPD Outcomes with a Digital Adherence Support Package: Findings from MAGNIFY
An interview with Prof. David Price and Prof. David Halpin.
Findings from a Phase 2b Trial Evaluating RT234, a Drug-Device Combination for Pulmonary Arterial Hypertension: Raymond Benza, ATS 2025
Breaking the Biofilm Barrier – A New Approach to Combatting Ventilator-Associated Pneumonia in ICU Patients: Frank MP van Haren, ATS 2025
Targeting a Rare and Aggressive Lung Cancer: A Study of Inhaled Osimertinib for Malignant Pleural Mesothelioma: Mural Quadros, ATS 2025
Cite: ATS 2025 Highlights: Expert Insights and Key Takeaways in Respiratory Care. touchRESPIRATORY. 2 July 2025.
Editor: Victoria Smith, Senior Content Editor.
Disclosures: This short article was prepared by touchRESPIRATORY. touchRESPIRATORY utilize AI as an editorial tool (ChatGPT (GPT-4o) [Large language model]. https://chat.openai.com/chat.) The content was developed and edited by human editors. No fees or funding were associated with its publication.
Register now to receive the touchRESPIRATORY newsletter!
Don’t miss out on hearing about our latest peer reviewed articles, expert opinions, conference news, podcasts and more.
